Tevimbra by BeiGene for Muscle Invasive Bladder Cancer (MIBC): Likelihood of Approval

Tevimbra is under clinical development by BeiGene and currently in Phase II for Muscle Invasive Bladder Cancer (MIBC).

Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September – Biotech Investments

Issuer: Immunic AG / Key word(s): Conference 28.08.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Host

August 29, 2024

Lilly says its weight loss drugs Mounjaro and Zepbound shouldn’t be used for ‘cosmetic’ reasons

Eli Lilly says it wants people to stop using its drugs Zepbound and Mounjaro for “cosmetic weight loss,” publishing a letter Thursday saying that it

January 5, 2024

Butterfly Launches Next-Gen Point-of-Care Ultrasound System

What You Should Know: – Butterfly Network has unveiled its next-generation handheld ultrasound system, the Butterfly iQ3, marking a significant advancement in point-of-care ultrasound (POCUS)

February 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.